Amgen’s Parsabiv approved in Europe for sHPT treatment in adults with CKD
Parsabiv is a calcimimetic agent where a healthcare provider can administer it intravenously three times per week at the end of a hemodialysis session. A calcimimetic is a
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.
The Prospective Randomized Evaluation of CelecoxibIntegrated Safety vs. Ibuprofen Or Naproxen (Precision) demonstrated that Celebrex has similar cardiovascular risk as compared to prescription doses Of Ibuprofen and Naproxen. The findings contradict some of the researchers’ belief